AIM ImmunoTech (NYSE American: AIM) regained compliance with NYSE American continued listing standards for stockholders’ equity.
Through May–June 2026 warrant exercises and equity offerings, AIM raised about $8.5 million/b] in gross proceeds and believes stockholders’ equity now exceeds the minimum. The “.BC” below-compliance indicator will be removed, though monitoring continues.
Regains NYSE American continued listing compliance for stockholders’ equity standards
Approximately $8.5 million total gross proceeds from recent warrant exercises and offerings
Company believes stockholders’ equity now exceeds the $6.0 million minimum requirement
“.BC” below-compliance flag removed and issuer removed from noncompliant list
Negative
Multiple common stock and warrant issuances likely increase dilution for existing shareholders
Company remains subject to NYSE American continued listing monitoring procedures
News Market Reaction – AIM
-4.04%
21 alerts
-4.04%News Effect
+29.8%Peak Tracked
-12.5%Trough Tracked
-$461KValuation Impact
$10.94MMarket Cap
0.3xRel. Volume
On the day this news was published, AIM declined 4.04%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +29.8% during that session.
Argus tracked a trough of -12.5% from its starting point during tracking.
Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
This price movement removed approximately $461K from the company's valuation, bringing the market cap to $10.94M at that time.
This announcement confirms that AIM regained NYSE American compliance on stockholders’ equity after ...
Analysis
This announcement confirms that AIM regained NYSE American compliance on stockholders’ equity after several recent financings totaling more than $8 million in gross proceeds, bringing equity above the $6.0 million threshold. The exchange removed the “.BC” indicator, though AIM remains under continued monitoring. Against a backdrop of prior rights offerings and an effective $100 million shelf, investors may watch how future capital raises balance dilution with funding needs and how clinical milestones, especially DURIPANC, interact with this strengthened listing status.
Registered direct offering and private placement raising about $2.4M gross.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows large moves on financings and clinical milestones, with generally negative reactions to capital raises but strong positive reactions to key DURIPANC trial updates.
Recent Company History
Over the last month, AIM combined clinical milestones with multiple capital raises. A June 1 DURIPANC enrollment update saw a 120.35% move, and a June 8 interim DURIPANC progress report was followed by a 13.13% gain. By contrast, the May 20 and June 9 financings of about $2.4M and $2.65M coincided with moves of +5.69% and -20.5%. Today’s regained NYSE American equity compliance follows this financing-driven effort to strengthen the balance sheet.
Regulatory & Risk Context
Active S-3 Shelf · $100 million · Short Interest: 26.18%
Shelf Active
Short Interest
26.18% of shares outstanding
as of 2026-05-29Days to cover: 1
Active S-3 Shelf Registration
2025-06-27
$100 millionregistered capacity
An effective Form S-3/A shelf from June 27, 2025 authorizes up to $100 million of various securities, giving AIM flexibility to raise additional capital via offerings like the recent financings used to address its NYSE American stockholders’ equity requirements.
Key Terms
warrants, private placement, pre-funded warrants, stockholders’ equity, +1 more
5 terms
warrantsfinancial
"entered into a warrant exercise inducement offer letter agreement with certain a holder of existing warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
private placementfinancial
"and, in a concurrent private placement, Class I warrants to purchase up to 15,038,702 shares"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
pre-funded warrantsfinancial
"pre-funded warrants to purchase up to 1,782,616 shares of common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
stockholders’ equityfinancial
"regained compliance with NYSE American’s continued listing standards related to stockholders’ equity"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
NYSE American Company Guideregulatory
"resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide"
A handbook of rules and requirements that govern companies listed on the NYSE American market, covering eligibility to list, ongoing disclosure duties, corporate governance expectations, and trading practices. It matters to investors because it sets the minimum standards companies must meet to join and remain on that exchange — like a routine safety inspection that signals basic reliability and transparency — helping investors judge regulatory compliance, quality of public information, and potential risks to a stock’s value.
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with NYSE American’s continued listing standards related to stockholders’ equity.
On May 7, 2026, the Company entered into a warrant exercise inducement offer letter agreement with certain a holder of existing warrants, pursuant to which the holders agreed to exercise their warrants in cash at a reduced exercise price for aggregate gross proceeds of approximately $3.5 million in consideration of the Company’s agreement to issue new warrants upon such exercise. On May 21, 2026, the Company issued and sold 7,519,351 shares of common stock, par value $0.001 per share, and, in a concurrent private placement, Class I warrants to purchase up to 15,038,702 shares of common stock to certain investors for aggregate gross proceeds of approximately $2.4 million. On June 10, 2026, the Company issued and sold 2,554,119 shares of common stock and, in a concurrent private placement, 771,503 shares of common stock, pre-funded warrants to purchase up to 1,782,616 shares of common stock, and Class J warrants to purchase up to 10,216,476 shares of common stock to certain investors for aggregate gross proceeds of approximately $2.6 million. Following the closing of these transactions, the Company believes it currently has stockholders’ equity in excess of the $6.0 million minimum requirement.
The NYSE American formally notified the Company on June 12, 2026, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. As a result, the “below compliance” (“.BC”) indicator will be removed from the Company’s trading symbol for its common stock, and the Company will be removed from NYSE American’s list of noncompliant issuers on its website. The Company will remain subject to NYSE American’s continued listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: statements regarding the Company’s ability to maintain compliance with NYSE American continued listing standards; the Company’s stockholders’ equity position and its ability to remain above the $6.0 million minimum requirement; Ampligen’s potential efficacy and applicability in the treatment of Ebola virus disease and other conditions; the potential for prophylactic or early-onset therapeutic applications; the timing of commencement, enrollment, completion, and results of clinical trials; intellectual property expansion and regulatory progress; and the timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. For this press release, words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions, including Ebola virus disease. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
For a detailed discussion of these and other risk factors, please review the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company does not intend to update, and expressly disclaims any duty to update, any forward-looking statements to reflect events or circumstances after the date hereof or to reflect new information, actual results, revised expectations, or the occurrence of unanticipated events. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ
What does AIM (NYSE American: AIM) regaining NYSE American compliance mean for shareholders in June 2026?
AIM’s return to compliance means its stock now meets NYSE American’s stockholders’ equity listing standards. According to AIM ImmunoTech, the exchange confirmed all equity-related deficiencies were resolved, reducing immediate delisting risk while the company remains under continued listing monitoring procedures.
How did AIM ImmunoTech (AIM) resolve its stockholders’ equity deficiency with NYSE American?
AIM addressed its equity deficiency by completing warrant exercise inducements and multiple equity offerings. According to AIM ImmunoTech, these transactions generated gross proceeds of about $8.5 million, and the company believes stockholders’ equity is now above the $6.0 million NYSE American minimum requirement.
How much capital did AIM ImmunoTech (AIM) raise in May–June 2026 to regain NYSE American compliance?
AIM raised approximately $8.5 million in aggregate gross proceeds across several transactions. According to AIM ImmunoTech, these included a $3.5 million warrant exercise inducement, a $2.4 million May 21, 2026 offering, and a $2.6 million June 10, 2026 equity and warrant financing.
What happens to AIM stock’s “.BC” below-compliance indicator after the June 12, 2026 NYSE American notice?
After NYSE American confirmed compliance on June 12, 2026, AIM’s “.BC” tag will be removed from its trading symbol. According to AIM ImmunoTech, the company will also be taken off the exchange’s public list of noncompliant issuers.
Is AIM ImmunoTech (AIM) still monitored by NYSE American after resolving its equity deficiency in 2026?
Yes, AIM remains subject to NYSE American’s continued listing monitoring procedures even after regaining compliance. According to AIM ImmunoTech, the company intends to maintain strong financial discipline and governance to support ongoing adherence to the exchange’s stockholders’ equity requirements.
